Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies
FR Brennan, LD Morton, S Spindeldreher, A Kiessling… - MAbs, 2010 - Taylor & Francis
Most therapeutic monoclonal antibodies (mAbs) licensed for human use or in clinical
development are indicated for treatment of patients with cancer and inflammatory/autoimmune …
development are indicated for treatment of patients with cancer and inflammatory/autoimmune …
[HTML][HTML] Aggregation of Human Recombinant Monoclonal Antibodies Influences the Capacity of Dendritic Cells to Stimulate Adaptive T-Cell Responses In Vitro
…, J Krieg, MC Djidja, A Baban, S Spindeldreher… - PLoS …, 2014 - journals.plos.org
Subvisible proteinaceous particles which are present in all therapeutic protein formulations
are in the focus of intense discussions between health authorities, academics and …
are in the focus of intense discussions between health authorities, academics and …
Clustering of MHC–peptide complexes prior to their engagement in the immunological synapse: lipid raft and tetraspan microdomains
AB Vogt, S Spindeldreher… - Immunological reviews, 2002 - Wiley Online Library
Protein reorganization at the interface of a T cell and an antigen‐presenting cell (APC)
plays an important role in T cell activation. Imaging techniques reveal that reorganization of …
plays an important role in T cell activation. Imaging techniques reveal that reorganization of …
[HTML][HTML] Characterization of CD4 T cell epitopes of infliximab and rituximab identified from healthy donors
…, M Pallardy, F Carbonnel, S Spindeldreher… - Frontiers in …, 2017 - frontiersin.org
The chimeric antibodies anti-CD20 rituximab (Rtx) and anti-TNFα infliximab (Ifx) induce antidrug
antibodies (ADAs) in many patients with inflammatory diseases. Because of the key role …
antibodies (ADAs) in many patients with inflammatory diseases. Because of the key role …
Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low …
A Karle, S Spindeldreher, F Kolbinger - MAbs, 2016 - Taylor & Francis
Secukinumab is a human monoclonal antibody that selectively targets interleukin-17A and
has been demonstrated to be highly efficacious in the treatment of moderate to severe plaque …
has been demonstrated to be highly efficacious in the treatment of moderate to severe plaque …
[HTML][HTML] Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium
…, A Vultaggio, C Warnke, S Spindeldreher… - PLoS …, 2020 - journals.plos.org
Background Biopharmaceutical products (BPs) are widely used to treat autoimmune
diseases, but immunogenicity limits their efficacy for an important proportion of patients. Our …
diseases, but immunogenicity limits their efficacy for an important proportion of patients. Our …
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays
…, N Smith, G Terszowski, S Tourdot, S Spindeldreher - MAbs, 2022 - Taylor & Francis
A major impediment to successful use of therapeutic protein drugs is their ability to induce
anti-drug antibodies (ADA) that can alter treatment efficacy and safety in a significant number …
anti-drug antibodies (ADA) that can alter treatment efficacy and safety in a significant number …
[HTML][HTML] Secukinumab demonstrates significantly lower immunogenicity potential compared to ixekizumab
S Spindeldreher, B Maillère, E Correia, M Tenon… - Dermatology and …, 2018 - Springer
Introduction Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A,
has been shown to have significant efficacy in the treatment of moderate to severe …
has been shown to have significant efficacy in the treatment of moderate to severe …
T cell epitope mapping of secukinumab and ixekizumab in healthy donors
S Spindeldreher, A Karle, E Correia, M Tenon… - MAbs, 2020 - Taylor & Francis
Secukinumab, a human monoclonal antibody that selectively neutralizes IL-17A, has
consistently shown low anti-drug antibody responses in patients with psoriasis, psoriatic arthritis, …
consistently shown low anti-drug antibody responses in patients with psoriasis, psoriatic arthritis, …
Upregulation of the CLIP self peptide on mature dendritic cells antagonizes T helper type 1 polarization
Dendritic cells (DCs) initiate and regulate immunity against foreign and self antigens. Here
we identified more than 200 individual major histocompatibility complex class II–associated …
we identified more than 200 individual major histocompatibility complex class II–associated …